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Abstract
Objective: To identify factors predictive of poor prognosis in women with stage III nonserous epithelial
ovarian cancer (EOC) who had undergone maximal or optimal primary cytoreductive surgery (CRS) fol-
lowed by six cycles of intravenous carboplatin/paclitaxel chemotherapy.
Methods: A multicenter, retrospective department database review was performed to identify patients with
stage III nonserous EOC who had undergone maximal or optimal primary CRS followed by six cycles of car-
boplatin/paclitaxel chemotherapy at seven gynecological oncology centers in Turkey. Demographic, clinico-
pathological and survival data were collected.
Results: A total of 218 women met the inclusion criteria. Of these, 64 (29.4%) patients had endometrioid,
61 (28%) had mucinous, 54 (24.8%) had clear-cell and 39 (17.9%) had mixed epithelial tumors. Fifty-five
(25.2%) patients underwent maximal CRS, whereas 163 (74.8%) had optimal debulking. With a median
follow-up of 31.5 months, the 5-year progression-free survival (PFS) and overall survival (OS) rates were
34.8% and 44.2%, respectively. Bilaterality (hazard ratio [HR] 1.44, 95% CI 1.01–2.056; P = 0.04), age
(HR 2.25, 95% CI 1.176–4.323; P = 0.014) and maximal cytoreduction (HR 0.34, 95% CI 0.202–0.58; P < 0.001)
were found to be independent prognostic factors for PFS. However, age (HR 2.6, 95% CI 1.215–5.591;
P = 0.014) and maximal cytoreduction (HR 0.31, 95% CI 0.166–0.615; P < 0.001) were defined as independent
prognostic factors for OS.
Conclusion: The extent of CRS seems to be the only modifiable prognostic factor associated with stage III
nonserous EOC. Complete cytoreduction to no gross residual disease should be the main goal of manage-
ment in these women.
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Introduction
Nowadays, it is well known that epithelial ovarian
cancer (EOC) is not a homogenous disease.1 Rather,
EOCs are represented by a number of molecularly
distinct diseases broadly defined by histotype with
different routes of spread, patterns of relapse,
response to chemotherapy and prognosis.2
Primary cytoreductive surgery (CRS) and taxane-/
platinum-based adjuvant chemotherapy are the cor-
nerstones of the initial treatment for all histological
subtypes of EOC.3,4 Nevertheless, prognosis is vari-
able, largely depending on the quality of primary
CRS and the time of development of platinum resis-
tance. Therefore, advanced EOC represents a hetero-
geneous group regarding the outcome after initial
management.5
Established prognostic factors for stage III EOC
include age,6,7 performance status (PS),6 extent of
residual disease (RD)6,7 and histology.7 Nevertheless,
previous studies investigating the prognostic factors
for advanced EOC suffer from several limitations,
such as heterogeneous study populations (inclusion of
patients with stage III and IV disease together),8–11
analyzing serous and nonserous malignant tumors
simultaneously,6–15 small number of patients with
nonserous EOC7,9–13 and the variation in adjuvant
chemotherapy regimens.9,11,12,14 Although it has been
well known for a long time that the quality of pri-
mary CRS is the strongest predictor of outcome,16,17
the extent of RD after primary CRS was not an inclu-
sion criterion in most of the previous studies, and
patients with maximal, optimal and suboptimal CRS
were generally analyzed simultaneously.6,8,10–12 It
seems plausible to adjust the optimality of primary
CRS and adjuvant chemotherapy for the evaluation of
prognostic factors for stage III EOC. In addition, it is
difficult to claim that older series do reflect the cur-
rent practice in terms of primary CRS and adjuvant
chemotherapy.12,13,15
Previous studies investigating the prognostic fac-
tors for stage III EOC consistently analyzed serous
and nonserous tumors together and included patients
mostly with serous EOC.6,7,12,13 Therefore, prognostic
factors for stage III nonserous EOC have not been
delineated clearly. From the current perspective that
different histotypes in EOC probably represent differ-
ent disease entities,18 we wondered whether the
established prognostic factors for all histotypes6,7,12,13
are also valid when nonserous malignant tumors are
analyzed as a separate group. Given the low
frequency of nonserous histotypes, we designed this
multicenter retrospective study in order to shed some
light on this issue with the aid of a well-defined
homogenous study population. The purpose of the
current study was to identify factors predictive of
poor prognosis in women with stage III nonserous
EOC who had undergone maximal or optimal pri-
mary CRS followed by six cycles of intravenous
(IV) carboplatin/paclitaxel chemotherapy.
Methods
Study design and eligibility
Medical records of women who underwent primary
surgical treatment for EOC between January 2007 and
December 2016 at seven gynecological oncology cen-
ters in Turkey were retrospectively reviewed. The
study protocol was approved by the local institutional
review boards. All patients provided informed con-
sent regarding research use of their medical informa-
tion at admission.
The study population included women who had
nonserous EOC (i.e., endometrioid, clear-cell, mucin-
ous and mixed subtypes) with histopathologically
proven stage III19disease. Women were included if
they had undergone primary surgical treatment,
including total hysterectomy plus bilateral salpingo-
oopherectomy, with bilateral pelvic and para-aortic
lymphadenectomy and other surgical procedures,
resulting in maximal or optimal CRS. All patients had
to have RD of 1 cm or less in order to be eligible.
Patients who were cytoreduced to greater than 1 cm
of RD were excluded. Because this study focused only
on women with nonserous EOC, women with high-
and low-grade serous carcinoma were excluded, as
well as patients having no lymphadenectomy. We
also excluded patients who received neoadjuvant che-
motherapy, women with synchronous malignancies
and those with incomplete medical records. A PS of
0 (normal activity) or 1 (symptomatic and fully ambu-
latory) was also an eligibility criterion. Women with a
PS ≥ 2 were excluded. Patients with coexisting medi-
cal comorbidities were excluded as this undoubtedly
influences the decision-making process of a surgeon
regarding whether to undertake an aggressive CRS.
Clinical information
Patient data were extracted from seven institutions
with maintained EOC databases. After selecting the
eligible cases, the following information was
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abstracted from medical records: demographic charac-
teristics, preoperative serum cancer antigen
125 (CA 125) level, date and type of surgical proce-
dure, presence or absence of ascites, the status of peri-
toneal cytology examination (negative, or positive),
bilaterality, size of RD after surgery, stage of disease,
time to recurrence, length of follow-up and survival.
Tumor characteristics were abstracted from original
pathology reports. Data were collected from centers
with an online standardized form. All operations
were performed by gynecological oncologists with the
intent to achieve optimal cytoreduction. RD after pri-
mary CRS was recorded according to the assessment
by the surgeon. Lymphadenectomy was performed
after completion of other cytoreductive procedures.
All patients underwent detailed preoperative and sur-
gical exploration to exclude primary colorectal and
appendiceal carcinomas.
All pathological specimens from primary surgery
were examined and interpreted by gynecological
pathologists of the participating institutions who had
experience in gynecological malignancies. Nonserous
EOC was diagnosed after examination of permanent
sections. Histological classification was performed
with the criteria defined by the World Health Organi-
zation (WHO).20,21 Architectural grading was defined
by standard International Federation of Gynecology
and Obstetrics (FIGO) criteria. Clear-cell carcinomas
were neither graded nor assigned as grade 3 in this
study. Cases diagnosed as high-grade endometrioid
were not removed from the endometrioid group.
The current study investigated cases with mixed
nonserous histologies (including mucinous, clear-cell,
endometrioid and transitional cell types) as a separate
group and did not assign mixed tumors according to
the dominant component. Mixed tumors were diag-
nosed according to the WHO definition, in that more
than one cell type was present, and the minority com-
ponent accounted for at least 10% of the tumor.
Mixed tumors containing serous component were
excluded. For the purposes of this study, only pure
tumors were classified as endometrioid, clear-cell or
mucinous, whereas tumors with more than one cell
type were classified as mixed. All tumors were staged
according to the 2014 FIGO staging system.19 In
patients treated before 2014, stage was determined
retrospectively on the basis of surgical and pathologi-
cal assessment.
The treatment policies were decided by the attend-
ing physician or by the multidisciplinary tumor board
at each participating institution. Adjuvant
chemotherapy was administered to all patients. The
standard primary chemotherapy regimen included
paclitaxel 175 mg/m2 plus carboplatin dosed at an
area under curve of 5 or 6 every 21 days for six
cycles. Targeted agents were not used to treat any of
the patients during primary treatment.
Patients returned for follow-up evaluation every
3 months for the first 2 years, every 6 months for
the next 3 years and annually thereafter. Computed
tomography or magnetic resonance imaging was
performed annually. Survival data were last calcu-
lated on 31st December 2016. The survival status of
the patients was determined as alive or dead at the
time of the last follow-up. For all study subjects
with a recorded death, this was confirmed by per-
forming a social security death index search.
Definitions
Baseline PS was defined according to the Gynecologic
Oncology Group (GOG) criteria, and only patients
with a PS of 0 (normal activity) and 1 (symptomatic
and fully ambulatory) were included in the current
study in order to overcome the confounding effect of
PS on the measured outcome.
Maximal cytoreduction was defined as no gross RD
(microscopic RD) after primary CRS. Optimal cytore-
duction was defined as less than or equal to 1 cm
maximal diameter of the largest residual tumor nod-
ule at the completion of the primary operation. Sub-
optimal cytoreduction was defined as >1 cm of
RD. Lymphadenectomy was defined as the perfor-
mance of pelvic and para-aortic LN dissection at the
same time. We defined pelvic lymphadenectomy as
the removal of lymphatic tissue in the external, inter-
nal and common iliac and obturator regions. Para-
aortic lymphadenectomy was defined as removal of
the lymphatic tissue over the inferior vena cava and
aorta, beginning at the level of aortic bifurcation up to
the left renal vessels.
Progression-free survival (PFS) was defined as the
time, in months, from the date of primary surgery
until the date of documented recurrence on the basis
of clinical examination or radiological imaging; death
from any cause, whichever occurred first; or the date
of last contact for patients remaining alive without
recurrent disease. Patients who had no active ovarian
cancer at the last contact were censored in the PFS
analysis. Overall survival (OS) was calculated as the
time period, in moths, between the date of primary
surgery to the date of death or the last contact. Sur-
viving patients were censored at their last known
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follow-up. As treatment after relapse was not uniform
and varied among institutions that participated in the
current study, the primary end-point was chosen
as PFS.
Statistical analysis
Statistical analyses were performed using the statisti-
cal software package SPSS version 23.0 (IBM Corp.,
Armonk, NY, USA). The data were expressed as
median and range for continuous variables. Binary
variables were reported as counts and percentages.
Survival analysis was based on the Kaplan–Meier
method, and the results were compared using a
log-rank test. Cox regression analysis was used to
determine factors affecting PFS and OS, presented as
hazard ratios (HRs) and 95% confidence intervals
(CI), unadjusted or adjusted for all factors. All variables
with a P value <0.05 in the univariate analysis were
included in the multivariate analysis. A P value <0.05
was considered to indicate statistical significance.
Results
During the study period, 367 women with stage III
nonserous EOC were treated at seven participating
centers. We excluded 23 patients who had no lympha-
denectomy, 17 women who received neoadjuvant che-
motherapy and 9 women with incomplete medical
records. One hundred patients who received subopti-
mal debulking were also excluded. Therefore, the pre-
sent analysis addresses the remaining 218 women.
The rate of suboptimal CRS was found to be 31.4%
(100/318) in the entire cohort. The inclusion process
of the patients and the suboptimal CRS rates with
regard to the histotypes are demonstrated in Table 1.
Of 218 women who met the inclusion criteria,
64 (29.4%) patients had endometrioid, 61 (28%) had
mucinous, 54 (24.8%) had clear-cell and 39 (17.9%)
had mixed epithelial tumors. The median age of the
patients was 54 (range, 18–78) years, and the median
duration of follow-up was 31.5 (range, 1–120) months.
There were 55 (25.2%) women with stage IIIA1,
14 (6.4%) with stage IIIA2, 34 (15.6%) with stage IIIB
and 115 (52.8%) with stage IIIC disease. Fifty-five
(25.2%) patients underwent maximal CRS, whereas
163 (74.8%) had optimal debulking. Table 2 summa-
rizes the clinicopathological characteristics of the
study population.
For the entire cohort, the 5-year PFS was 34.8%,
with a median PFS of 28 months (95% confidence
interval [CI] 20.58–35.42, Standard Error [SE]: 3.785).
The median PFS for endometrioid, clear-cell, mixed
epithelial and mucinous histotypes were 38, 24,
22 and 20 months, respectively (Fig. 1a).
For 55 (25.2%) women undergoing maximal CRS,
the median PFS was not reached yet, whereas the
corresponding figure was found to be 22 months
(95% CI 16.3–27.7 months) for 163 (74.8%) patients
who received optimal debulking (P < 0.001)
(Fig. 2). The median OS for women with maximal
CRS was significantly longer than that of women
undergoing optimal CRS (not reached yet vs
39 months [95% CI 30.6–47.4 months], respectively;
P < 0.001) (Fig. 3).
Univariate analysis demonstrated age (≤ 50 vs
≥70 years) (P = 0.039), bilaterality (P = 0.001), stage
(stage IIIA1 vs others) (P = 0.002), omental
Table 1 The inclusion process of the patients and the suboptimal cytoreductive surgery rates with regard to the
histotypes
Clear-cell Endometrioid Mixed Mucinous Total
Total number of cases identified 93 94 71 109 367
Number of cases with incomplete
medical records
2 2 3 2 9
Number of cases who received
neoadjuvant chemotherapy
5 3 6 3 17
Number of cases who received no
lymphadenectomy
5 3 3 12 23
Number of cases who received
suboptimal debulking
27 22 20 31 100
Number of cases excluded 39 30 32 48 149
Suboptimal CRS rate 27/81
(33.3%)
22/86
(25.6%)
20/59
(33.9%)
31/92
(33.7%)
100/318
(31.4%)
Number of patients included 54 64 39 61 218
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involvement (P < 0.001), peritoneal involvement
(P = 0.001) and gross RD ≤ 1 cm (P < 0.001) to be sig-
nificant factors for decreased PFS (Table 2). At the
end of multivariate analysis, bilaterality (HR 1.44,
95% CI 1.01–2.056; P = 0.04), age (≤ 50 vs ≥70 years)
(HR 2.25, 95% CI 1.176–4.323; P = 0.014) and maximal
cytoreduction (HR 0.34, 95% CI 0.202–0.58; P < 0.001)
remained independent prognostic factors for PFS
(Table 3).
The 5-year OS of the entire cohort was 44.2%, with
a median overall survival of 47 months (95% CI
36.12–57.88, SE: 5.55). The median OS for endome-
trioid, clear-cell, mixed epithelial and mucinous histo-
types were 49 months, 44 months, not reached yet
and 45 months, respectively (Fig. 1b).
Univariate analysis demonstrated age (P = 0.007),
bilaterality (P = 0.008), stage (stage IIIA1 vs others)
(P = 0.001), omental involvement (P < 0.001), perito-
neal involvement (P = 0.001) and gross RD ≤ 1 cm
(P < 0.001) to be significant factors for decreased OS
(Table 3). At the end of multivariate analysis, age
(51–69 years vs ≤50 years (HR 1.73, 95% CI 1.23–2.66;
P = 0.013), (≤ 50 vs ≥70 years) (HR 2.6, 95% CI
1.215–5.591; P = 0.014) and maximal cytoreduction
(HR 0.31, 95% CI 0.166–0.615; P < 0.001) remained
independent prognostic factors for OS (Table 4). At
the time of reporting, of 218 women with stage III
nonserous EOC, 109 (50%) were dead, whereas
109 (50%) were alive.
Discussion
This study represents a retrospective analysis of
218 patients with stage III nonserous EOC who have
undergone maximal or optimal CRS followed by six
cycles of IV carboplatin/paclitaxel chemotherapy.
Our results indicated age ≤ 50 years, achievement of
maximal cytoreduction and unilaterality of the tumor
as independent prognostic factors for prolonged PFS.
Although the number of patients is relatively limited,
to the best of our knowledge, this is the first study
reporting on the prognostic factors for stage III
nonserous EOC.
A large GOG study identified factors of poor prog-
nosis in a similarly treated population of women with
stage III EOC.6 This study included 1895 patients with
stage III EOC who had undergone primary CRS fol-
lowed by platinum/paclitaxel chemotherapy. Age,
PS, tumor histology and residual tumor volume were
independent predictors of outcome in patients with
stage III EOC.6 However, non-serous histologies con-
stituted 21.3% (n = 404) of their study population,
whereas 35% of patients (n = 667) underwent subopti-
mal CRS in that study.6
Landrum et al.7 have reported that histology, age
and extent of RD are identified as statistically signifi-
cant variables for OS in a cohort of 428 patients with
stage III EOC undergoing optimal CRS followed by
intraperitoneal paclitaxel/ platinum chemotherapy. It
Figure 1 The progression-free survival and overall survival curves of women with endometrioid, clear cell, mixed epithe-
lial and mucinous histotypes in stage III nonserous epithelial ovarian cancer.
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should be noted that patients with clear-cell and
mucinous histology comprised only 6.3% (n = 27) of
their study population. However, our findings point-
ing out age and extent of RD as independent
prognostic factors for OS are in agreement with those
of Landrum et al.7
Extent of RD, PS and adjuvant chemotherapy regi-
men were adjusted, and the confounding effects of
these variables were minimized for the evaluation of
Figure 2 The progression-free survival curves of
women who have undergone maximal and optimal
cytoreduction in stage III nonserous epithelial ovarian
cancer.
Figure 3 The overall survival curves of women who
have undergone maximal and optimal cytoreduction
in stage III nonserous epithelial ovarian cancer.
Table 2 Baseline characteristics of the patients
Characteristic Values
Age, years (median) 54 (18–78)
Menopausal status, n (%)
Postmenopausal 138 (63.3%)
Premenopausal 80 (36.7%)
Histopathology, n (%)
Endometrioid 64 (29.4%)
Mucinous 61 (28%)
Mixed 39 (17.9%)
Clear 54 (24.8%)
Serum CA 125 (median, IU/ml) 240 (5–9523)
≥240 IU/mL 109 (50%)
<240 IU/mL 109 (50%)
Bilaterality, n (%)
Present 107 (49.1%)
Absent 111 (50.9%)
Ascites, n (%)
Present 122 (56%)
Absent 96 (44%)
Peritoneal cytology, n (%)
Positive 148 (67.9%)
Negative 70 (32.1%)
Grade, n (%)
1 31 (14.2%)
2 57 (26.1%)
3 76 (34.9%)
Number of LNs removed (median)
Number of pelvic LNs removed 25 (10–93)
Number of para-aortic LNs
removed
12 (5–66)
Retroperitoneal LN metastases, n (%)
Present 121 (55.5%)
Absent 97 (44.5%)
Peritoneal involvement, n (%)
Yes 141 (64.7%)
No 77 (35.3%)
Omental involvement, n (%)
Yes 131 (60.1%)
No 87 (39.9%)
Debulking surgery, n (%)
Optimal 163 (74.8%)
Maximal 55 (25.2%)
Stage, n (%)
IIIA1 55 (25.2%)
IIIA2 14 (6.4%)
IIIB 34 (15.6%)
IIIC 115 (52.8%)
Status, n (%)
Alive 109 (50%)
Dead 109 (50%)
LN, lymph node; n, number.
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prognostic factors for stage III nonserous EOC in the
current study. However, age appeared to be an inde-
pendent prognostic factor for PFS and OS in multi-
variate analysis, demonstrating that those patients≥
70 years were 2.2 times more likely to have
decreased PFS when compared to those ≤ 50 years.
Landrum et al.7 have stated that patient age stands
as a prognostic factor for survival independent of
RD, PS, grade and stage. The authors suggested that
better understanding of the changes in tumor biol-
ogy or immune response in older patients may lead
to new insights into the best treatment methods for
the rapidly increasing population.7 It should be
noted that age at the time of diagnosis for patients
with EOC has been consistently recognized as an
independent prognostic factor in previous
studies.7,8,12,22–24
It is increasingly appreciated that tumor cell type
correlates with epidemiological risk factors, “BRCA
1 or 2” mutation status, differences in gene expression
profile and genetic events during oncogenesis and
response to chemotherapy.14Nevertheless, information
on the prognostic significance of histology in the con-
text of changing therapeutic standards is limited.5 The
Table 3 Univariate and multivariate analyses for prognostic factors for progression-free survival
Variable Univariate analysis Multivariate analysis
PFS† (%) P HR 95% CI P
Grade
1 43.9 0.39
2–3 34.9
Stage
IIIA1 54.1 0.002 0.96 0.55–1.69 NS
IIIA2-IIIB-IIIC 28.7
Serum CA 125 (median, IU/mL)
≥240 IU/mL 33.6 0.75
<240 IU/mL 35.9
Ascites
Present 36.4 0.32
Absent 32.6
Retroperitoneal LN metastases
Present 40.1 0.12
Absent 28.4
Peritoneal cytology
Positive 35.0 0.4
Negative 34.7
Omental involvement
Yes 25.7 <0.001 1.36 0.87–2.10 NS
No 48.6
Peritoneal involvement
Yes 26.9 0.001 1.28 0.81–2.02 NS
No 49.0
Histopathology
Mucinous 39.0
Endometriod 27.1
Clear 37.9 0.4
Mixed 29.6
Age, y
≤ 50 27.6 0.03
51–69 25.0 1.42 0.98–2.05 0.062
≥70 2.25 1.17–4.32 0.014
Bilaterality
Present 22.7 0.001 1.44 1.01–2.05 0.044
Absent 46.6
Debulking
Optimal 24.8
Maximal 66.7 < 0.001 0.34 0.202–0.580 <0.001
†5-year progression free survival rate. CI, confidence interval; HR, hazard ratio; PFS, progression-free survival.
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prognostic significance of histotype is controversial in
stage III EOC given the relative rarity of histological
subtypes other than serous.25 Most studies describing
the role of tumor histology in prognosis have focused
on mucinous and clear-cell tumors.5,26–30 However,
histological subtype has been reported as an indepen-
dent prognostic factor for stage III–IV EOC.9,10 In con-
trast, Chi et al.11and Bristow et al.31 showed that
histological subtype was not a significant prognostic
factor in earlier studies.
Winter et al.6 reported that mucinous or clear-cell
histology was associated with a worse PFS and OS
compared with serous carcinomas. In a meta-analysis
of 8704 women with stage III–IV EOC, it has been
shown that the prognoses of women with mucinous
tumors are worse than those with serous tumors, and
the prognoses of patients with the clear-cell carcino-
mas are unlikely to be better.8 Nevertheless, histotype
did not seem to have prognostic significance in
women with stage III nonserous EOC in the current
study. Our findings do not agree with previous
reports showing the prognostic significance of histo-
logical subtype in advanced EOC.6–10,12 The prognos-
tic significance of the tumor histology seems to be
consistent when serous malignant tumors are com-
pared with nonserous malignant tumors, whereas its
Table 4 Univariate and multivariate analyses for prognostic factors for overall survival
Variable Univariate analysis Multivariate analysis
OS† (%) P HR 95% CI P
Grade
1 55.5 0.32
2–3 43.6
Stage
IIIA1 66.7 0.001 0.88 0.45–1.72 NS
IIIA2-IIIB-IIIC 37.5
Bilaterality
Present 31.4 0.008 1.29 0.87–1.93 NS
Absent 57.5
Serum CA 125 (median, IU/ml)
≥240 IU/mL 38.8 0.558
<240 IU/mL 49.6
Ascites
Present 39.4 0.17
Absent 50.3
Retroperitoneal LN metastases
Present 47.4 0.17
Absent 40.4
Peritoneal cytology
Positive 41.7 0.33
Negative 49.3
Omental involvement
Yes 32.9 <0.001 1.47 0.90–2.42 NS
No 61.9
Peritoneal involvement
Yes 35.7 0.001 1.21 0.72–2.01 NS
No 59.7
Histological subtypes
Mucinous 47
Endometriod 42 0.38
Clear 40
Mixed 50
Age, y
≤ 50 57
51–69 36.1 1.73 1.23–2.667 0.013
≥70 42 0.007 2.6 1.215–5.59 0.014
Debulking
Optimal 33.8
Maximal 81.2 <0.001 0.31 0.166–0.615 0.001
†5-year overall survival. CI, confidence interval; HR: hazard ratio.
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prognostic significance disappears when nonserous
malignant tumors are studied as a separate group.
The volume of RD after primary CRS depends on
the number and the size of tumor elements.12 In this
retrospective study, RD status after primary CRS was
recorded according to the assessment of the attending
surgeon. We were not able to define the number of
lesions left after primary CRS. However, the maxi-
mum diameter of the greatest residual tumor nodule
is a very crude estimate of RD, but it still provided
valuable prognostic information in our study as it did
in previous studies.7,12,17 There was a statistically sig-
nificant PFS and OS advantage for patients with no
gross RD compared to those with macroscopic RD
≤1 cm in the current study. Our study has provided
further information that the prognostic significance of
the extent of RD stands even within a population of
patients with ≤ 1 cm of RD.
Our analysis has shown that the extent of RD is an
independent predictor of OS, whereas the substage of
the disease is not. Our finding are in line with that of
Landrum et al.7who suggested that efforts to reduce the
tumor burden to no gross RDmight mitigate the impact
of stage. In addition, it has been reported that residual
tumor size was associated with an increased risk of
death for advanced nonserous EOC, whereas taxane-
based chemotherapy was not a prognostic factor.9
Several potential limitations of our study warrant
consideration. First, the retrospective nature of the
study cannot exclude any bias. Second, treatment
after recurrence was not uniform and varied among
institutions that participated in the study. Therefore,
our findings associated with OS should be met cau-
tiously. Third, our study was restricted by the lack of
a central pathology review. Although a comprehen-
sive central pathology review would be ideal, patients
with nonserous EOC included in the current study do
reflect the ‘real-world’ diagnosis and practice in our
country. We used information from routine practice
in order to assess prognoses of women with stage III
nonserous EOC. These women were homogeneously
diagnosed and treated in tertiary referral centers, and
histopathological evaluation was performed by highly
experienced gynecological pathologists. Despite the
abovementioned limitations, our findings provide
additional information to the body of knowledge on
this topic.
The strength of the current study, compared with
previous reports, is mainly the homogeneity of the
patient population and the treatment, which provides
a precise estimation of the magnitude of the effect
while controlling for confounder influences. The
homogenous structure of our study seems to reduce
the possibility of confounding and enhances the reli-
ability of the prognostic effects of those have been
estimated.
Our findings indicate that maximal cytoreduction is
the only modifiable prognostic factor associated with
stage III nonserous EOC. Maximal surgical effort
seems to currently be the best option for the initial
treatment of these women as PFS and OS seem to be
superior whenever maximal cytoreduction has been
achieved. We have to emphasize that women with no
gross RD following primary CRS had survival rates
that exceed any rates previously reported in stage III
nonserous EOC treated with the current standard
chemotherapy.
At any rate, the retrospective nature of our study
does not permit us to draw definitive conclusions as
similar previous studies. It should be noted that the
results of the current study are limited only to
patients who can be cytoreduced to 1 cm or
less of RD.
We conclude that complete cytoreduction to no
gross RD should be the main goal of management in
women with stage III nonserous EOC, and it seems
reasonable to perform maximal CRS whenever possi-
ble in those patients. However, further exploration of
molecular markers and biologic pathways to better
characterize the behavior of these rare histotypes is
warranted.
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